Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phyto A+ Brightening Treatment is a topical corrective moisturizer developed by SkinCeuticals, formulated to address skin discoloration, uneven texture, and redness. The product contains a synergistic blend of 3% azelaic acid, 2% alpha arbutin, and a 5.75% phyto-botanical complex (including cucumber, thyme, and olive leaf extracts). It functions primarily by inhibiting tyrosinase, the key enzyme in melanin synthesis, thereby reducing hyperpigmentation and improving skin clarity. The Austin Institute for Clinical Research has conducted Phase 4 clinical trials evaluating its efficacy and tolerability when used in conjunction with non-ablative laser treatments for facial dyschromia and photoaging across diverse skin types, including Fitzpatrick types I-VI and individuals of Asian descent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Phyto A+ Brightening Treatment.